"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 2 | 5 |
| 1999 | 3 | 4 | 7 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 3 | 1 | 4 |
| 2011 | 4 | 1 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 0 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 4 | 2 | 6 |
| 2018 | 6 | 1 | 7 |
| 2019 | 5 | 2 | 7 |
| 2020 | 11 | 5 | 16 |
| 2021 | 12 | 6 | 18 |
| 2022 | 6 | 1 | 7 |
| 2023 | 9 | 0 | 9 |
| 2024 | 5 | 6 | 11 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
HIV pre-exposure prophylaxis re-initiation among men who have sex with men: a multi-center cohort study in China. Sex Health. 2025 Mar; 22.
-
Knowledge, Attitudes, and Perspectives of Women Who Have Migrated from Sub-Saharan Africa to France Toward HIV Pre-Exposure Prophylaxis in a Family Planning Center. AIDS Patient Care STDS. 2024 Nov; 38(11):507-516.
-
Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir/rilpivirine among early adopters in three U.S. clinics. J Int AIDS Soc. 2024 Nov; 27(11):e26394.
-
The impact of HIV antiretroviral therapy on gut microbiota: the need for well-designed longitudinal studies. J Infect Dev Ctries. 2024 Oct 31; 18(10):1461-1473.
-
PrEPárate: Evaluation of a Community-Driven PrEP Social Marketing Intervention Tailored to Latino/a/x Individuals. AIDS Behav. 2024 Dec; 28(12):4069-4078.
-
Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed. J Acquir Immune Defic Syndr. 2024 07 01; 96(3):280-289.
-
Psychiatry and Family Medicine Residents' Likelihood of Prescribing HIV Pre-exposure Prophylaxis to Patients With Mental Illness and HIV Vulnerability. J Acquir Immune Defic Syndr. 2024 07 01; 96(3):231-240.
-
Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers. J Int AIDS Soc. 2024 Jul; 27 Suppl 3:e26319.
-
Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States. AIDS Behav. 2024 Jul; 28(7):2226-2238.
-
"There hasn't been a push to identify patients in the emergency department"-Staff perspectives on automated identification of candidates for pre-exposure prophylaxis (PrEP): A qualitative study. PLoS One. 2024; 19(3):e0300540.